Neurosearch and GlaxoSmithKlein initiate second phase 2 study on depression drug |
|
|
|
Published
:
Tue, 24 Apr 2007 10:50
|
COPENHAGEN (Thomson Financial) - Danish pharmaceutical company Neurosearch said it has, in a strategic alliance with GlaxoSmithKlein (GSK), initiated the second of two phase 2 studies on the depression treatment candidate NS2359.The initiation of the study does not affect Neurosearch's financial guidance for 2007, the group said.The new study will be conducted in parallel with the first, which was started in December 2006, it added.NS2359 has a new drug profile which is expected to yield important benefits compared to existing depression treatments, including improvement of cognitive functions and possibly an earlier onset of action, said Neurosearch.GSK was granted a licence for NS2359 under an agreement from December 2003, and is financing all future development costs, while Neurosearch is entitled to receive milestone payments and royalties on sales.gustav.sandstrom@thomson.comgs/ambCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
Print this Story
Neurosearch partner Abbott Laboratories intiates phase 2 study for ADHD drug 